BioLife Solutions, Inc. (BLFS) News
Filter BLFS News Items
BLFS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BLFS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BLFS News From Around the Web
Below are the latest news stories about BIOLIFE SOLUTIONS INC that investors may wish to consider to help them evaluate BLFS as an investment opportunity.
Is BioLife Solutions, Inc. (NASDAQ:BLFS) Potentially Undervalued?BioLife Solutions, Inc. ( NASDAQ:BLFS ), might not be a large cap stock, but it saw a significant share price rise of... |
BioLife Solutions Appoints Tony J. Hunt to its Board of DirectorsBioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. |
3 US Stocks Estimated To Be Trading At Discounts Up To 40.9%As the U.S. stock market experiences fluctuations with major indices like the Dow Jones and Nasdaq showing mixed movements, investors are keenly observing sectors such as technology for potential opportunities amid ongoing economic developments. In this environment, identifying undervalued stocks can be crucial, as these investments may offer significant potential when trading at discounts compared to their intrinsic value. |
Estimating The Intrinsic Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)Key Insights BioLife Solutions' estimated fair value is US$32.75 based on 2 Stage Free Cash Flow to Equity BioLife... |
BioLife Solutions, Inc. (NASDAQ:BLFS) Just Reported And Analysts Have Been Cutting Their EstimatesBioLife Solutions, Inc. ( NASDAQ:BLFS ) just released its third-quarter report and things are looking bullish. The... |
BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer SubsidiaryBioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ("Custom Biogenic Systems" or "CBS"), for $6.1 million in cash. |
BioLife Solutions Third Quarter 2024 Earnings: Beats ExpectationsBioLife Solutions ( NASDAQ:BLFS ) Third Quarter 2024 Results Key Financial Results Revenue: US$30.6m (down 8.3% from 3Q... |
BioLife Solutions Inc (BLFS) Q3 2024 Earnings Call Highlights: Strategic Divestitures and ...BioLife Solutions Inc (BLFS) reports robust revenue growth and improved margins, while navigating challenges in its freezer business and macroeconomic risks. |
BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue EstimatesBioLife Solutions (BLFS) delivered earnings and revenue surprises of 77.78% and 21.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
BioLife Solutions Reports Third Quarter 2024 Financial ResultsBioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today announced financial results for the three and nine months ended September 30, 2024 and updated revenue guidance for 2024. |